GATHERING AND CRITICALLY ASSESSING THE SCIENTIFIC EVIDENCE TO SUBSTANTIATE HEALTH BENEFITS OF VITAMIN K2
Task Force Information
Objectives
Vitamin K2, a lesser-known but crucial nutrient, plays a vital role in bone and cardiovascular health, among other functions. Despite its significance, awareness and understanding of Vitamin K2 remain relatively low. The formation of this Task Force represents a significant step towards bridging this gap. Its primary objective is to critically review the scientific evidence supporting the various health benefits attributed to vitamin K2. Additionally, the Task Force aims to identify and evaluate potential biomarkers for monitoring vitamin K2 status, as well as conduct a comprehensive nutrition economic study to determine the potential healthcare cost savings for Europe associated with vitamin K2 supplementation.
Task Force Members
| Lena Leder | Kappa Bioscience, a Balchem Company | Nutrition Science Manager | NO |
| Delphine Saulnier | Novonesis | Health Science & Technology Lead | DE |
| Jean-Francois Jeanne | Gnosis by Lesaffre | Team Manager | FR |
| Anne Birkett | DSM-Firmenich | Science Translation and Advocacy Segment Lead | SW |
| Isabelle Guelinckx | ILSI Europe | Executive Director at interim | BE |
| Naomi Venlet | ILSI Europe | Scientific Project Manager | BE |
*Scientific Advisor
For more detailed information, please contact Naomi Venlet at nvenlet@ilsieurope.be or Isabelle Guelinckx at iguelinckx@ilsieurope.be
Activity Overview
In the pipeline
- Non-systematic review of the evidence available on the health benefits associated with vitamin K2, including a grading of the evidence strength.
- Review of existing biomarkers in view of building a consensus on the optimal maker to monitor vitamin K2 status.
- Nutrition economic study determining the potential healthcare cost savings for Europe linked to vitamin K2 supplementation.
Expert Groups
Coming soon...
Publications
Coming soon...
Multimedia
One-Pager
Poster (Aug 2023)
